Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal
AUTOR(ES)
Kondro, Wayne
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=527327Documentos Relacionados
- Rofecoxib (Vioxx) voluntarily withdrawn from market
- What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex)
- Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten
- Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs
- Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed adverse events before licensing